C4 therapeutics to participate in bmo biopharma spotlight series

Watertown, mass., feb. 11, 2021 (globe newswire) -- c4 therapeutics, inc. (c4t) (nasdaq: cccc), a biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease-causing proteins through degradation, today announced that the company will participate in the bmo biopharma spotlight series: proteins – degraders and other next gen technologies, including a panel discussion, “ligating” competitors for collaboration in the protein degradation space, on thursday, february 18, 2021 at 10:30 a.m. et.
CCCC Ratings Summary
CCCC Quant Ranking